Abstract
PURPOSE
To estimate local control, survival, and toxicity associated with a 3-fraction (3F)
image-guided brachytherapy (IGBT) regimen compared to longer fraction (LF) for cervical
cancer.
METHODS
150 patients treated between 2015-2020 with 3F (24Gy in 3 fractions) or LF (28...30
Gy in 4-5 fractions) were reviewed. The primary outcome was 2-year local failure.
We compared overall survival (OS), disease-free survival (DFS), hospitalizations,
and toxicity.
RESULTS
There were 32 patients in the 3F group and 118 in the LF group, with a median follow
up of 22 months. The 3F had worse performance status (p = 0.01) but otherwise similar characteristics. The 2-year local failure rate was
3.6% (95% CI 0%, 10.6%) for 3F, and 7.5% (95% CI 2.4%, 12.6%) for LF. The univariable
hazard ratio (HR) for local failure for 3F was 0.43 (0.05, 3.43; p = 0.43). Moreover, 2 of 32 (6.3%) 3F patients experienced Grade ...3 toxicity compared
to 7 of 118 (5.9%) LF patients (p = 1.0), with no difference in hospitalization within 2 years (p = 0.66) and no treatment-related deaths.
CONCLUSIONS
Local control was excellent, with long term survival and toxicity similar between
the groups. These findings support consideration of 3F.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to BrachytherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.Lancet Glob Health. 2020; 8: E191-E203
- HPV Vaccination and the Risk of Invasive Cervical Cancer.N Eng J Med. 2020; 383: 1340-1348https://doi.org/10.1056/NEJMoa1917338
- Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis.Lancet North Am Ed. 2001; 358: 781-786https://doi.org/10.1016/S0140-6736(01)05965-7
- Tumor and treatment factors improving outcome in stage III-B cervix cancer.Int J Radiat Oncol*Biology*Phys. 1991; 20: 95-100https://doi.org/10.1016/0360-3016(91)90143-R
- Trends in the utilization of brachytherapy in cervical cancer in the United States.Int J Radiat Oncol*Biol*Phys. 2013; 87: 111-119https://doi.org/10.1016/j.ijrobp.2013.05.033
- Brachytherapy in gynecologic cancers: why is it underused?.Curr Oncol Rep. 2016; 18: 26https://doi.org/10.1007/s11912-016-0508-y
- Brachytherapy: where has it gone?.JCO. 2015; 33: 980-982https://doi.org/10.1200/JCO.2014.59.8128
- The unique issues with brachytherapy in low- and middle-income countries.Semin Radiat Oncol. 2017; 27: 136-142https://doi.org/10.1016/j.semradonc.2016.11.005
- Understanding the underutilization of cervical brachytherapy for locally advanced cervical cancer.Brachytherapy. 2019; 18: 361-369https://doi.org/10.1016/j.brachy.2018.12.002
- Influence of treatment center and hospital volume on survival for locally advanced cervical cancer.Gynecol Oncol. 2015; 139: 506-512
- Brachytherapy in the treatment of cervical cancer: a review.Int J Womens Health. 2014; 6: 555-564https://doi.org/10.2147/IJWH.S46247
- A prospective cohort study to compare treatment results between 2 fractionation schedules of high-dose-rate intracavitary brachytherapy (HDR-ICBT) in patients with cervical cancer.Int J Radiat Oncol*Biol*Phys. 2013; 85: 123-128https://doi.org/10.1016/j.ijrobp.2012.03.045
- Literature analysis of high dose rate brachytherapy fractionation schedules in the treatment of cervical cancer: is there an optimal fractionation schedule?.Int J Radiat Oncol*Biol*Phys. 1999; 43: 359-366https://doi.org/10.1016/S0360-3016(98)00387-3
- Underutilization of brachytherapy and disparities in survival for patients with cervical cancer in California.Gynecol Oncol. 2018; 150: 73-78https://doi.org/10.1016/j.ygyno.2018.04.563
- Socioeconomic and racial determinants of brachytherapy utilization for cervical cancer: concerns for widening disparities.JCO Oncol Pract. 2021; 17: e1958-e1967
- COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation.Brachytherapy. 2020; 19: 401-411
- Optimized planning target volume for intact cervical cancer.Int J Radiat Oncol*Biol*Phys. 2012; 83: 1500-1505https://doi.org/10.1016/j.ijrobp.2011.10.027
- Prospective validation of a high dimensional shape model for organ motion in intact cervical cancer.Int J Radiat Oncol*Biol*Phys. 2016; 96: 801-807https://doi.org/10.1016/j.ijrobp.2016.08.015
- Iterative stepwise regression imputation using standard and robust methods.Comput Stats & Data Anal. 2011; 55: 2793-2806https://doi.org/10.1016/j.csda.2011.04.012
R Ref: R Core Team (2020). R: a language and environment for statistical computing. Available at: https://www.R-project.org/ assessed date: Feb 10, 2021.
- Comparison of high and low dose rate remote afterloading for cervix cancer and the importance of fractionation.Int J Radiat Oncol*Biol*Phys. 1991; 21: 1425-1434https://doi.org/10.1016/0360-3016(91)90316-V
- A Phase II trial of stereotactic ablative radiation therapy as a boost for locally advanced cervical cancer.Int J Radiat Oncol*Biol*Phys. 2020; 106: 464-471https://doi.org/10.1016/j.ijrobp.2019.10.042
- National Cancer data base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements.Int J Radiat Oncol*Biol*Phys. 2014; 90: 1083-1090https://doi.org/10.1016/j.ijrobp.2014.07.017
- Patterns of radiation therapy practice for patients treated for intact cervical cancer in 2005 to 2007: a quality research in radiation oncology study.Int J Radiat Oncol*Biol*Phys. 2014; 89: 249-256https://doi.org/10.1016/j.ijrobp.2013.11.228
- Patterns of care with brachytherapy for cervical cancer.Int J Gynecol Cancer. 2014; 24https://doi.org/10.1097/IGC.0000000000000276
- Posttraumatic stress disorder after high-dose-rate brachytherapy for cervical cancer with 2 fractions in 1 application under spinal/epidural anesthesia: incidence and risk factors.Int J Radiat Oncol*Biol*Phys. 2014; 89: 260-267https://doi.org/10.1016/j.ijrobp.2014.02.018
- Five-year survival outcomes with two different high dose rate brachytherapy schedules used in the treatment of cervical carcinoma.Therap Radiol Oncol. 2022; 6: 2https://doi.org/10.21037/tro-21-19
- A comparative analysis of two different dose fractionation regimens of high dose rate intracavitary brachytherapy in treatment of carcinoma of uterine cervix: a prospective randomized study.J Clin Diagn Res. 2017; 11: XC06
- Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline.Pract Radiat Oncol. 2020; 10 (Epub 2020 May 18. PMID: 32473857): 220-234https://doi.org/10.1016/j.prro.2020.04.002
- Radiobiological analysis of outcomes using external beam radiotherapy plus high dose-rate brachytherapy (4x7 Gy or 2x9 Gy) for cervical cancer in a multi-institution trial.Int J Radiat Oncol Biol Phys. 2017; 99: 1313-1314
- Metabolic Response on Post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer.Int J Radiat Oncol*Biol*Phys. 2012; 83: 185-190https://doi.org/10.1016/j.ijrobp.2011.05.053
Article info
Publication history
Published online: January 09, 2023
Accepted:
December 16,
2022
Received in revised form:
December 12,
2022
Received:
September 8,
2022
Publication stage
In Press Corrected ProofFootnotes
Disclosures: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. There are no actual or potential conflicts of interest to disclose.
Identification
Copyright
© 2023 Published by Elsevier Inc. on behalf of American Brachytherapy Society.
